162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
| Autor: | Hamilton, E.P., Shapiro, C.L., Boni, V., Martin Jimenez, M., Del Conte, G., Cortés, J., Agrawal, L., Arkenau, H-T., Tan, A.R., Debruyne, P.R., Minchom, A.R., Rutten, A., Valdes-Albini, F., Yu, E., Suto, F., Cheng, F-C., Augustine, B., Cheng, B., Barrios, D., Hurvitz, S.A. |
|---|---|
| Zdroj: | In Annals of Oncology May 2022 33 Supplement 3:S196-S196 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|